

Bibliography

1. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA, 2002, "RNA aptamers as reversible antagonists of coagulation factor IXa", *Nature* 419, 90-94.
2. Kuliczkowski W, Floyd J, Malinin E, Serebruany V, 2010, "Aptamers: the emerging class of future anticoagulation for vascular disease", *Expert Rev. Cardiovasc Ther* 8(4), 503-507.
3. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. 2006, "First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity", *Circulation* 114, 2490-2497.
4. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. 2008, "Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease", *Circulation* 117, 2865-74.
5. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC. 2008, "A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor", *Journal of Thrombosis Haemostasis* 6, 789-96.
6. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Aberle LH, Greenbaum AB, Fry ET, Alexander JH, Rusconi CP, Becker RC. 2009, "First clinical application of an actively reversible direct factor IXa inhibitor in elective percutaneous coronary intervention", *European Heart Journal* 30, 101.
7. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske SL, Alexander JH, Harrington RA, Rusconi CP, Becker RC. 2010, "First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention", *Circulation* 122: 614 - 622.
8. Eikelboom JW, Zelenkofske SL, Rusconi CP. 2010, "Coagulation Factor IXa as a target for treatment and prophylaxis of venous thromboembolism", *Arterioscler Thromb Vasc Biol* 30(3), 382-387.
9. Zelenkofske SL, Rusconi CP, Damiento CM, Wargin W, Medlock M, Becker R. 2010, "Subcutaneous RB006, a direct FIXa inhibitor provides prolonged anticoagulation with rapid reversal; the first clinical experience with the REG2 system", Presented at Atherothrombosis and Vascular Biology meeting, April 2010.